Pharma Majors Face 'Patent Cliff'

Multinational pharmaceutical companies face significant declines in revenue when the patents on their best-selling drugs expire, allowing for the diffusion of cheaper copies. BMI identifies two companies as particularly vulnerable to generic competition in 2014; Teva Pharmaceuticals based in Israel and Britain's AstraZeneca Plc. We look at what generic competition means for these two firms as well as for the industry as a whole. This podcast features Pharmaceutical & Healthcare analyst Asif Ashraf.

This blog is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: India, United Kingdom, Global, Israel
Tags: Generic Pharmaceuticals, Pharmaceuticals, Teva, AstraZeneca, Patented Medicines, Asif Ashraf

Related products in our Store...

Check out our most popular reports below or view more in our store

Access all of our latest analysis, data and forecasts - request a trial